Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Br J Haematol. 2023 Aug;202(4):718-719. doi: 10.1111/bjh.18868. Epub 2023 May 15.
In a large multicentre retrospective real-world analysis, Hess and colleagues describe outcomes in post-Bruton tyrosine kinase inhibitor (BTKi) mantle cell lymphoma patients managed in clinical practice prior to availability of brexucabtagene autoleucel (Tecartus). Outcome data not only provide a useful benchmark for future studies but also highlight the great challenges that still lie ahead in managing this challenging patient cohort. Commentary on: Hess et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 2023;202:749-759.
在一项大型多中心回顾性真实世界分析中，Hess 及其同事描述了 Bruton 酪氨酸激酶抑制剂 (BTKi) 治疗后套细胞淋巴瘤患者在 brexucabtagene autoleucel（Tecartus）可用之前在临床实践中的治疗结果。这些结果不仅为未来的研究提供了有用的基准，也凸显了管理这一具有挑战性的患者群体所面临的巨大挑战。述评：Hess 等人。欧洲 BTKi 治疗失败后复发/难治性套细胞淋巴瘤患者的真实世界经验：SCHOLAR-2 回顾性图表审查研究。英国血液学杂志 2023;202:749-759.
